Citigroup
BIVV

Citigroup’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Citigroup’s Portfolio BIVV Stock Details BIVV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-31,400
Closed -$1.69M – 7804
2017
Q4 		$1.69M Buy
31,400
+25,200
+406% +$1.38M ﹤0.01% 2838
2017
Q3 		$354K Buy
+6,200
New +$363K ﹤0.01% 4463

Other funds holding BIVV

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
ACS
Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return

Citigroup's BIVV Position: Q1 2018 in Review

Citigroup sold out of Bioverativ Inc. Common Stock (BIVV) in Q1 2018, closing a stake of 109,342 shares — an estimated $5.89M sold.

Citigroup first reported a position in BIVV in Q1 2017 and held it in 4 quarters. The position peaked at $6.59M in Q2 2017. 2 funds tracked by Wall St. Rank hold BIVV as of Q1 2018.

  • Citigroup reported no remaining Bioverativ Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Citigroup sold 109,342 Bioverativ Inc. Common Stock shares in Q1 2018, an estimated $5.89M.
  • Citigroup first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 4 quarters.
  • Citigroup's Bioverativ Inc. Common Stock position peaked at $6.59M in Q2 2017.
  • 2 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q1 2018.

Based on Citigroup's 13F filing for Q1 2018, filed 11 May 2018.